相关实验视频
Updated: Jan 12, 2026

09:22
In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
Published on: January 2, 2015
18.9K
脂蛋白E基因4等位基因和粉样β基因介导着与tau相关的网络分解
1School of Medicine, Iran University of Medical Sciences, Tehran 14535, Iran.
Brain communications
|November 3, 2025
概括
阿尔茨海默病涉及tau的扩散和功能断开,由阿波利波蛋白E基因4等位基因和β-粉样蛋白加速. 这些因素调解对大脑连接的影响,建议针对载体进行有针对性的干预.
科学领域:
- 神经科学是一个神经科学.
- 生物医学成像技术 生物医学成像技术
- 遗传学 是一个遗传学.
背景情况:
- 阿尔茨海默病 (AD) 与大脑功能连接的改变有关,由团和粉样β斑块驱动.
- 人们认为陶聚合物会导致功能断开和认知衰退,像子一样扩散.
- 阿波利波蛋白E (APOE) 基因4等位基因和粉样β基因在调解tau相关功能断开中的作用尚不清楚.
研究的目的:
- 调查APOE ε4状态和粉样β的调解作用对tau扩散和功能连接性之间的关系.
- 分析病理如何影响随着时间的推移功能连接.
主要方法:
- 来自ADNI和HABS队列的纵向tau-PET和静止状态fMRI数据的分析.
- 使用高斯混合模型识别tau-PET中心.
- 功能连接的调解分析,tau传播,粉样β状态和APOE ε4基因型.
主要成果:
- 积率在与基线积中心连接更强的地区较高.
- APOE ε4和粉样β状态调解了功能连接和tau传播之间的关联.
- 的传播破坏了局部连接,这是由APOE ε4和粉样β阳性介导的过程.
结论:
- 聚合物通过功能连接传播,破坏本地大脑连接.
- APOE ε4和粉样β状态在与tau相关的功能断开中起着调解作用.
- 针对APOE ε4载体和粉样β阳性个体的早期干预措施可能有助于减轻tau的传播和功能断开.
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Amyloid Fibrils
11.6K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
11.6K
Amyloid Fibrils
6.3K
6.3K
Alzheimer's Disease: Treatment
801
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
801

